Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers

Advanced Drug Delivery Reviews

Volumn 97, Issue , 2016, Pages 156-173

  Poluzzi, Chiara ^a   Iozzo, Renato V ^b   Schaefer, Liliana ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Angiogenesis; Autophagy; Collagen type XVIII; Perlecan; Proteoglycan

Indexed keywords

BUILDINGS; CELL DEATH; CELLS; COLLAGEN; CYTOLOGY; DISEASES; ENDOTHELIAL CELLS; TUMORS;

ANGIOGENESIS; AUTOPHAGY; BIOLOGICAL MECHANISMS; C-TERMINAL SEGMENTS; ESSENTIAL CHARACTERISTIC; EXTRACELLULAR MATRICES; PERLECAN; PROTEOGLYCANS;

BLOOD VESSELS;

COLLAGEN TYPE 18; ENDOREPELLIN; ENDOSTATIN; INTEGRIN RECEPTOR; PERLECAN; PROTEOHEPARAN SULFATE; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VERY LATE ACTIVATION ANTIGEN 2; ENDOREPELLIN PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ACUTE MYELOBLASTIC LEUKEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BASEMENT MEMBRANE; BLADDER CARCINOMA; BRAIN TUMOR; BREAST CARCINOMA; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; COLORECTAL CARCINOMA; DOWN REGULATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE THERAPY; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; KIDNEY CARCINOMA; LEWIS CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CARCINOMA; OXIDATIVE STRESS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TESTIS CARCINOMA; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ANIMALS; ENDOSTATINS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS;

EID: 84957801865     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.10.012     Document Type: Review

References (299)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
2. Ramchandran R., Karumanchi S.A., Hanai J., Alper S.L., Sukhatme V.P. Cellular actions and signaling by endostatin. Crit. Rev. Eukaryot. Gene Expr. 2002, 12:175-191.
3. Iozzo R.V., Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. Febs. J. 2010, 277:3864-3875.
4. Iozzo R.V. Matrix proteoglycans: from molecular design to cellular function. Annu. Rev. Biochem. 1998, 67:609-652.
5. Timpl R. Proteoglycans of basement membranes. Experientia 1993, 49:417-428.
6. Levine B., Mizushima N., Virgin H.W. Autophagy in immunity and inflammation. Nature 2011, 469:323-335.
7. Mizushima N. Autophagy: process and function. Genes Dev. 2007, 21:2861-2873.
8. Deretic V. Autophagy in immunity and cell-autonomous defense against intracellular microbes. Immunol. Rev. 2011, 240:92-104.
9. Novak I., Kirkin V., McEwan D.G., Zhang J., Wild P., Rozenknop A., Rogov V., Lohr F., Popovic D., Occhipinti A., Reichert A.S., Terzic J., Dotsch V., Ney P.A., Dikic I. Nix is a selective autophagy receptor for mitochondrial clearance. EMBO Rep. 2010, 11:45-51.
10. Yamamoto A., Cremona M.L., Rothman J.E. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J. Cell Biol. 2006, 172:719-731.
11. Gonzalez-Polo R.A., Boya P., Pauleau A.L., Jalil A., Larochette N., Souquere S., Eskelinen E.L., Pierron G., Saftig P., Kroemer G. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J. Cell Sci. 2005, 118:3091-3102.
12. Lee I.H., Kawai Y., Fergusson M.M., Rovira I.I., Bishop A.J.R., Motoyama N., Cao L., Finkel T. Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress. Science 2012, 336:225-228.
13. Gozuacik D., Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004, 23:2891-2906.
14. Tsujimoto Y., Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ. 2005, 12:1528-1534.
15. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 2011, 15:1013-1031.
16. Neill T., Schaefer L., Iozzo R.V. Instructive roles of extracellular matrix on autophagy. Am J Pathol 2014, 184:2146-2153.
17. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp. Cell Res. 2006, 312:594-607.
18. Brech A., Ahlquist T., Lothe R.A., Stenmark H. Autophagy in tumour suppression and promotion. Mol. Oncol. 2009, 3:366-375.
19. Hippert M.M., O'Toole P.S., Thorburn A. Autophagy in cancer: good, bad, or both?. Cancer Res. 2006, 66:9349-9351.
20. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
21. Choi K.S. Autophagy and cancer. Exp. Mol. Med. 2012, 44:109-120.
22. Levine B. Unraveling the role of autophagy in cancer. Autophagy 2006, 2:65-66.
23. Poluzzi C., Casulli J., Goyal A., Mercer T.J., Neill T., Iozzo R.V. Endorepellin evokes autophagy in endothelial cells. J Biol Chem 2014, 289:16114-16128.
24. Nguyen T.M., Subramanian I.V., Xiao X., Ghosh G., Nguyen P., Kelekar A., Ramakrishnan S. Endostatin induces autophagy in endothelial cells by modulating Beclin 1 and beta-catenin levels. J. Cell. Mol. Med. 2009, 13:3687-3698.
25. Nguyen T.M., Subramanian I.V., Kelekar A., Ramakrishnan S. Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood 2007, 109:4793-4802.
26. Marneros A.G., Olsen B.R. Physiological role of collagen XVIII and endostatin. FASEB J. 2005, 19:716-728.
27. Halfter W., Dong S., Schurer B., Cole G.J. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J. Biol. Chem. 1998, 273:25404-25412.
28. Oh S.P., Kamagata Y., Muragaki Y., Timmons S., Ooshima A., Olsen B.R. Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:4229-4233.
29. Dong S., Cole G.J., Halfter W. Expression of collagen XVIII and localization of its glycosaminoglycan attachment sites. J. Biol. Chem. 2003, 278:1700-1707.
30. Li D., Clark C.C., Myers J.C. Basement membrane zone type XV collagen is a disulfide-bonded chondroitin sulfate proteoglycan in human tissues and cultured cells. J. Biol. Chem. 2000, 275:22339-22347.
31. Oh S.P., Warman M.L., Seldin M.F., Cheng S.D., Knoll J.H., Timmons S., Olsen B.R. Cloning of cDNA and genomic DNA encoding human type XVIII collagen and localization of the alpha 1(XVIII) collagen gene to mouse chromosome 10 and human chromosome 21. Genomics 1994, 19:494-499.
32. Muragaki Y., Timmons S., Griffith C.M., Oh S.P., Fadel B., Quertermous T., Olsen B.R. Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:8763-8767.
33. Rehn M., Pihlajaniemi T. Identification of three N-terminal ends of type XVIII collagen chains and tissue-specific differences in the expression of the corresponding transcripts. The longest form contains a novel motif homologous to rat and Drosophila frizzled proteins. J. Biol. Chem. 1995, 270:4705-4711.
34. Elamaa H., Snellman A., Rehn M., Autio-Harmainen H., Pihlajaniemi T. Characterization of the human type XVIII collagen gene and proteolytic processing and tissue location of the variant containing a frizzled motif. Matrix Biol. 2003, 22:427-442.
35. Saarela J., Ylikarppa R., Rehn M., Purmonen S., Pihlajaniemi T. Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol. 1998, 16:319-328.
36. Suzuki O.T., Sertie A.L., Der Kaloustian V.M., Kok F., Carpenter M., Murray J., Czeizel A.E., Kliemann S.E., Rosemberg S., Monteiro M., Olsen B.R., Passos-Bueno M.R. Molecular analysis of collagen XVIII reveals novel mutations, presence of a third isoform, and possible genetic heterogeneity in Knobloch syndrome. Am. J. Hum. Genet. 2002, 71:1320-1329.
37. Fukai N., Eklund L., Marneros A.G., Oh S.P., Keene D.R., Tamarkin L., Niemela M., Ilves M., Li E., Pihlajaniemi T., Olsen B.R. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J. 2002, 21:1535-1544.
38. Robinson C.J., Mulloy B., Gallagher J.T., Stringer S.E. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J. Biol. Chem. 2006, 281:1731-1740.
39. Ylikarppa R., Eklund L., Sormunen R., Kontiola A.I., Utriainen A., Maatta M., Fukai N., Olsen B.R., Pihlajaniemi T. Lack of type XVIII collagen results in anterior ocular defects. FASEB J. 2003, 17:2257-2259.
40. Hurskainen M., Eklund L., Hagg P.O., Fruttiger M., Sormunen R., Ilves M., Pihlajaniemi T. Abnormal maturation of the retinal vasculature in type XVIII collagen/endostatin deficient mice and changes in retinal glial cells due to lack of collagen types XV and XVIII. FASEB J. 2005, 19:1564-1566.
41. Eklund L., Piuhola J., Komulainen J., Sormunen R., Ongvarrasopone C., Fassler R., Muona A., Ilves M., Ruskoaho H., Takala T.E., Pihlajaniemi T. Lack of type XV collagen causes a skeletal myopathy and cardiovascular defects in mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1194-1199.
42. Moulton K.S., Olsen B.R., Sonn S., Fukai N., Zurakowski D., Zeng X. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 2004, 110:1330-1336.
43. Li Q., Olsen B.R. Increased angiogenic response in aortic explants of collagen XVIII/endostatin-null mice. Am. J. Pathol. 2004, 165:415-424.
44. Zaferani A., Talsma D.T., Yazdani S., Celie J.W., Aikio M., Heljasvaara R., Navis G.J., Pihlajaniemi T., van den Born J. Basement membrane zone collagens XV and XVIII/proteoglycans mediate leukocyte influx in renal ischemia/reperfusion. PLoS One 2014, 9:e106732.
45. Aikio M., Elamaa H., Vicente D., Izzi V., Kaur I., Seppinen L., Speedy H.E., Kaminska D., Kuusisto S., Sormunen R., Heljasvaara R., Jones E.L., Muilu M., Jauhiainen M., Pihlajamaki J., Savolainen M.J., Shoulders C.C., Pihlajaniemi T. Specific collagen XVIII isoforms promote adipose tissue accrual via mechanisms determining adipocyte number and affect fat deposition. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E3043-E3052.
46. Menzel O., Bekkeheien R.C., Reymond A., Fukai N., Boye E., Kosztolanyi G., Aftimos S., Deutsch S., Scott H.S., Olsen B.R., Antonarakis S.E., Guipponi M. Knobloch syndrome: novel mutations in COL18A1, evidence for genetic heterogeneity, and a functionally impaired polymorphism in endostatin. Hum. Mutat. 2004, 23:77-84.
47. Sertie A.L., Sossi V., Camargo A.A., Zatz M., Brahe C., Passos-Bueno M.R. Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure (Knobloch syndrome). Hum. Mol. Genet. 2000, 9:2051-2058.
48. Ackley B.D., Crew J.R., Elamaa H., Pihlajaniemi T., Kuo C.J., Kramer J.M. The NC1/endostatin domain of Caenorhabditis elegans type XVIII collagen affects cell migration and axon guidance. J. Cell Biol. 2001, 152:1219-1232.
49. Li M., Liu F., Sun P., Gao Y., Chen H., Liu H., Wang M., Chen J., Zhao Y. Correlations between serum levels of vascular endothelial growth factor and endostatin with clinical pathological characteristics of patients with gastrointestinal cancers. Hepatogastroenterology 2012, 59:1865-1868.
50. Wang Z.H., Zhu Z.T., Xiao X.Y., Sun J. Correlation of serum levels of endostatin with tumor stage in gastric cancer: a systematic review and meta-analysis. Biomed. Res. Int. 2015, 2015:623939.
51. Singhal S., Vachani A., Antin-Ozerkis D., Kaiser L.R., Albelda S.M. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin. Cancer Res. 2005, 11:3974-3986.
52. Franklin O., Ohlund D., Lundin C., Oman M., Naredi P., Wang W., Sund M. Combining conventional and stroma-derived tumour markers in pancreatic ductal adenocarcinoma. Cancer Biomark. 2015, 15:1-10.
53. Ohlund D., Ardnor B., Oman M., Naredi P., Sund M. Expression pattern and circulating levels of endostatin in patients with pancreas cancer. Int. J. Cancer 2008, 122:2805-2810.
54. Ohlund D., Lundin C., Ardnor B., Oman M., Naredi P., Sund M. Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br. J. Cancer 2009, 101:91-97.
55. Iizasa T., Chang H., Suzuki M., Otsuji M., Yokoi S., Chiyo M., Motohashi S., Yasufuku K., Sekine Y., Iyoda A., Shibuya K., Hiroshima K., Fujisawa T. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin. Cancer Res. 2004, 10:5361-5366.
56. Chang H., Iizasa T., Shibuya K., Iyoda A., Suzuki M., Moriya Y., Liu T.L., Hiwasa T., Hiroshima K., Fujisawa T. Increased expression of collagen XVIII and its prognostic value in nonsmall cell lung carcinoma. Cancer 2004, 100:1665-1672.
57. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989, 161:851-858.
58. Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., Bouck N.P. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:6624-6628.
59. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Cao Y., Moses M., Lane W.S., Sage E.H., Folkman J. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb. Symp. Quant. Biol. 1994, 59:471-482.
60. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
61. Ferreras M., Felbor U., Lenhard T., Olsen B.R., Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000, 486:247-251.
62. Sasaki T., Fukai N., Mann K., Gohring W., Olsen B.R., Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J. 1998, 17:4249-4256.
63. Felbor U., Dreier L., Bryant R.A., Ploegh H.L., Olsen B.R., Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 2000, 19:1187-1194.
64. Wen W., Moses M.A., Wiederschain D., Arbiser J.L., Folkman J. The generation of endostatin is mediated by elastase. Cancer Res. 1999, 59:6052-6056.
65. Standker L., Schrader M., Kanse S.M., Jurgens M., Forssmann W.G., Preissner K.T. Isolation and characterization of the circulating form of human endostatin. FEBS Lett. 1997, 420:129-133.
66. Ding Y.H., Javaherian K., Lo K.M., Chopra R., Boehm T., Lanciotti J., Harris B.A., Li Y., Shapiro R., Hohenester E., Timpl R., Folkman J., Wiley D.C. Zinc-dependent dimers observed in crystals of human endostatin. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:10443-10448.
67. Sasaki T., Hohenester E., Timpl R. Structure and function of collagen-derived endostatin inhibitors of angiogenesis. IUBMB Life 2002, 53:77-84.
68. Hohenester E., Sasaki T., Olsen B.R., Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J. 1998, 17:1656-1664.
69. Boehm T., O'Reilly M S., Keough K., Shiloach J., Shapiro R., Folkman J. Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem. Biophys. Res. Commun. 1998, 252:190-194.
70. Tjin Tham Sjin R.M., Satchi-Fainaro R., Birsner A.E., Ramanujam V.M., Folkman J., Javaherian K. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res. 2005, 65:3656-3663.
71. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C., Pihlajaniemi T., Alitalo K., Vuori K. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1024-1029.
72. Sudhakar A., Sugimoto H., Yang C., Lively J., Zeisberg M., Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4766-4771.
73. Kim Y.M., Jang J.W., Lee O.H., Yeon J., Choi E.Y., Kim K.W., Lee S.T., Kwon Y.G. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 2000, 60:5410-5413.
74. Sasaki T., Larsson H., Kreuger J., Salmivirta M., Claesson-Welsh L., Lindahl U., Hohenester E., Timpl R. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J. 1999, 18:6240-6248.
75. Karumanchi S.A., Jha V., Ramchandran R., Karihaloo A., Tsiokas L., Chan B., Dhanabal M., Hanai J.I., Venkataraman G., Shriver Z., Keiser N., Kalluri R., Zeng H., Mukhopadhyay D., Chen R.L., Lander A.D., Hagihara K., Yamaguchi Y., Sasisekharan R., Cantley L., Sukhatme V.P. Cell surface glypicans are low-affinity endostatin receptors. Mol. Cell 2001, 7:811-822.
76. MacDonald N.J., Shivers W.Y., Narum D.L., Plum S.M., Wingard J.N., Fuhrmann S.R., Liang H., Holland-Linn J., Chen D.H., Sim B.K. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J. Biol. Chem. 2001, 276:25190-25196.
77. Wickstrom S.A., Alitalo K., Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res. 2002, 62:5580-5589.
78. Wickstrom S.A., Alitalo K., Keski-Oja J. Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J. Biol. Chem. 2003, 278:37895-37901.
79. Kim Y.M., Hwang S., Pyun B.J., Kim T.Y., Lee S.T., Gho Y.S., Kwon Y.G. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J. Biol. Chem. 2002, 277:27872-27879.
80. Hajitou A., Grignet C., Devy L., Berndt S., Blacher S., Deroanne C.F., Bajou K., Fong T., Chiang Y., Foidart J.M., Noel A. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 2002, 16:1802-1804.
81. Shi H., Huang Y., Zhou H., Song X., Yuan S., Fu Y., Luo Y. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007, 110:2899-2906.
82. Ginisty H., Sicard H., Roger B., Bouvet P. Structure and functions of nucleolin. J. Cell Sci. 1999, 112(Pt 6):761-772.
83. Dhanabal M., Ramchandran R., Volk R., Stillman I.E., Lombardo M., Iruela-Arispe M.L., Simons M., Sukhatme V.P. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res. 1999, 59:189-197.
84. Yamaguchi N., Anand-Apte B., Lee M., Sasaki T., Fukai N., Shapiro R., Que I., Lowik C., Timpl R., Olsen B.R. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 1999, 18:4414-4423.
85. Sim B.K., Fogler W.E., Zhou X.H., Liang H., Madsen J.W., Luu K., O'Reilly M.S., Tomaszewski J.E., Fortier A.H. Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 1999, 3:41-51.
86. Wickstrom S.A., Alitalo K., Keski-Oja J. Endostatin signaling and regulation of endothelial cell-matrix interactions. Adv. Cancer Res. 2005, 94:197-229.
87. Deryugina E.I., Quigley J.P. Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol. 2015, 44-46:94-112.
88. Shay G., Lynch C.C., Fingleton B. Moving targets: emerging roles for MMPs in cancer progression and metastasis. Matrix Biol. 2015, 44-46:200-206.
89. Nyberg P., Heikkila P., Sorsa T., Luostarinen J., Heljasvaara R., Stenman U.H., Pihlajaniemi T., Salo T. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J. Biol. Chem. 2003, 278:22404-22411.
90. Lee S.J., Jang J.W., Kim Y.M., Lee H.I., Jeon J.Y., Kwon Y.G., Lee S.T. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett. 2002, 519:147-152.
91. Shichiri M., Hirata Y. Antiangiogenesis signals by endostatin. FASEB J. 2001, 15:1044-1053.
92. Wickstrom S.A., Veikkola T., Rehn M., Pihlajaniemi T., Alitalo K., Keski-Oja J. Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells. Cancer Res. 2001, 61:6511-6516.
93. Hanai J., Gloy J., Karumanchi S.A., Kale S., Tang J., Hu G., Chan B., Ramchandran R., Jha V., Sukhatme V.P., Sokol S. Endostatin is a potential inhibitor of Wnt signaling. J. Cell Biol. 2002, 158:529-539.
94. Eriksson K., Magnusson P., Dixelius J., Claesson-Welsh L., Cross M.J. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett. 2003, 536:19-24.
95. Urbich C., Reissner A., Chavakis E., Dernbach E., Haendeler J., Fleming I., Zeiher A.M., Kaszkin M., Dimmeler S. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. 2002, 16:706-708.
96. Xu X., Mao W., Chen Q., Zhuang Q., Wang L., Dai J., Wang H., Huang Z. Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway. PLoS One 2014, 9:e107463.
97. Hanai J., Dhanabal M., Karumanchi S.A., Albanese C., Waterman M., Chan B., Ramchandran R., Pestell R., Sukhatme V.P. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J. Biol. Chem. 2002, 277:16464-16469.
98. Dhanabal M., Ramchandran R., Waterman M.J., Lu H., Knebelmann B., Segal M., Sukhatme V.P. Endostatin induces endothelial cell apoptosis. J. Biol. Chem. 1999, 274:11721-11726.
99. Dixelius J., Larsson H., Sasaki T., Holmqvist K., Lu L., Engstrom A., Timpl R., Welsh M., Claesson-Welsh L. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000, 95:3403-3411.
100. Ginisty H., Amalric F., Bouvet P. Nucleolin functions in the first step of ribosomal RNA processing. EMBO J. 1998, 17:1476-1486.
101. Erard M.S., Belenguer P., Caizergues-Ferrer M., Pantaloni A., Amalric F. A major nucleolar protein, nucleolin, induces chromatin decondensation by binding to histone H1. Eur. J. Biochem. 1988, 175:525-530.
102. Kharrat A., Derancourt J., Doree M., Amalric F., Erard M. Synergistic effect of histone H1 and nucleolin on chromatin condensation in mitosis: role of a phosphorylated heteromer. Biochemistry 1991, 30:10329-10336.
103. Christian S., Pilch J., Akerman M.E., Porkka K., Laakkonen P., Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol. 2003, 163:871-878.
104. Huang Y., Shi H., Zhou H., Song X., Yuan S., Luo Y. The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. Blood 2006, 107:3564-3571.
105. Yu Y., Moulton K.S., Khan M.K., Vineberg S., Boye E., Davis V.M., O'Donnell P.E., Bischoff J., Milstone D.S. E-selectin is required for the antiangiogenic activity of endostatin. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8005-8010.
106. Abdollahi A., Hahnfeldt P., Maercker C., Grone H.J., Debus J., Ansorge W., Folkman J., Hlatky L., Huber P.E. Endostatin's antiangiogenic signaling network. Mol. Cell 2004, 13:649-663.
107. Chau Y.P., Lin S.Y., Chen J.H., Tai M.H. Endostatin induces autophagic cell death in EAhy926 human endothelial cells. Histol. Histopathol. 2003, 18:715-726.
108. Goligorsky M.S., Chen J., Patschan S. Stress-induced premature senescence of endothelial cells: a perilous state between recovery and point of no return. Curr. Opin. Hematol. 2009, 16:215-219.
109. Iozzo R.V., Schaefer L. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 2015, 42:11-55.
110. Iozzo R.V. Basement membrane proteoglycans: from cellar to ceiling. Nat. Rev. Mol. Cell Biol. 2005, 6:646-656.
111. Hassell J., Yamada Y., Arikawa-Hirasawa E. Role of perlecan in skeletal development and diseases. Glycoconj. J. 2002, 19:263-267.
112. Farach-Carson M.C., Warren C.R., Harrington D.A., Carson D.D. Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders. Matrix Biol. 2014, 34:64-79.
113. Friedrich M.V., Schneider M., Timpl R., Baumgartner S. Perlecan domain V of Drosophila melanogaster. Sequence, recombinant analysis and tissue expression. Eur. J. Biochem. 2000, 267:3149-3159.
114. Rogalski T.M., Williams B.D., Mullen G.P., Moerman D.G. Products of the unc-52 gene in Caenorhabditis elegans are homologous to the core protein of the mammalian basement membrane heparan sulfate proteoglycan. Genes Dev. 1993, 7:1471-1484.
115. Iozzo R.V. Perlecan: a gem of a proteoglycan. Matrix Biol. 1994, 14:203-208.
116. Whitelock J.M., Melrose J., Iozzo R.V. Diverse cell signaling events modulated by perlecan. Biochemistry 2008, 47:11174-11183.
117. Hassell J.R., Robey P.G., Barrach H.J., Wilczek J., Rennard S.I., Martin G.R. Isolation of a heparan sulfate-containing proteoglycan from basement membrane. Proc. Natl. Acad. Sci. U. S. A. 1980, 77:4494-4498.
118. Rosenmann H., Meiner Z., Kahana E., Aladjem Z., Friedman G., Ben-Yehuda A., Grenader T., Wertman E., Abramsky O. An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 128B:123-125.
119. Cohen I.R., Grassel S., Murdoch A.D., Iozzo R.V. Structural characterization of the complete human perlecan gene and its promoter. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10404-10408.
120. Brown J.C., Sasaki T., Gohring W., Yamada Y., Timpl R. The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur. J. Biochem. 1997, 250:39-46.
121. Yurchenco P.D., Schittny J.C. Molecular architecture of basement membranes. FASEB J. 1990, 4:1577-1590.
122. Aviezer D., Hecht D., Safran M., Eisinger M., David G., Yayon A. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994, 79:1005-1013.
123. Whitelock J.M., Iozzo R.V. Heparan sulfate: a complex polymer charged with biological activity. Chem. Rev. 2005, 105:2745-2764.
124. Gohring W., Sasaki T., Heldin C.H., Timpl R. Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. Eur. J. Biochem. 1998, 255:60-66.
125. Mongiat M., Taylor K., Otto J., Aho S., Uitto J., Whitelock J.M., Iozzo R.V. The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7. J. Biol. Chem. 2000, 275:7095-7100.
126. Ghiselli G., Eichstetter I., Iozzo R.V. A role for the perlecan protein core in the activation of the keratinocyte growth factor receptor. Biochem. J. 2001, 359:153-163.
127. Sher I., Zisman-Rozen S., Eliahu L., Whitelock J.M., Maas-Szabowski N., Yamada Y., Breitkreutz D., Fusenig N.E., Arikawa-Hirasawa E., Iozzo R.V., Bergman R., Ron D. Targeting perlecan in human keratinocytes reveals novel roles for perlecan in epidermal formation. J. Biol. Chem. 2006, 281:5178-5187.
128. Smith S.M., West L.A., Hassell J.R. The core protein of growth plate perlecan binds FGF-18 and alters its mitogenic effect on chondrocytes. Arch. Biochem. Biophys. 2007, 468:244-251.
129. Chuang C.Y., Lord M.S., Melrose J., Rees M.D., Knox S.M., Freeman C., Iozzo R.V., Whitelock J.M. Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan. Biochemistry 2010, 49:5524-5532.
130. Mongiat M., Otto J., Oldershaw R., Ferrer F., Sato J.D., Iozzo R.V. Fibroblast growth factor-binding protein is a novel partner for perlecan protein core. J. Biol. Chem. 2001, 276:10263-10271.
131. Dodge G.R., Kovalszky I., Hassell J.R., Iozzo R.V. Transforming growth factor beta alters the expression of heparan sulfate proteoglycan in human colon carcinoma cells. J. Biol. Chem. 1990, 265:18023-18029.
132. Iozzo R.V., Pillarisetti J., Sharma B., Murdoch A.D., Danielson K.G., Uitto J., Mauviel A. Structural and functional characterization of the human perlecan gene promoter. Transcriptional activation by transforming growth factor-beta via a nuclear factor 1-binding element. J. Biol. Chem. 1997, 272:5219-5228.
133. Sharma B., Iozzo R.V. Transcriptional silencing of perlecan gene expression by interferon-gamma. J. Biol. Chem. 1998, 273:4642-4646.
134. Colombelli C., Palmisano M., Eshed-Eisenbach Y., Zambroni D., Pavoni E., Ferri C., Saccucci S., Nicole S., Soininen R., McKee K.K., Yurchenco P.D., Peles E., Wrabetz L., Feltri M.L. Perlecan is recruited by dystroglycan to nodes of Ranvier and binds the clustering molecule gliomedin. J. Cell Biol. 2015, 208:313-329.
135. Talts J.F., Andac Z., Gohring W., Brancaccio A., Timpl R. Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J. 1999, 18:863-870.
136. Timpl R., Tisi D., Talts J.F., Andac Z., Sasaki T., Hohenester E. Structure and function of laminin LG modules. Matrix Biol. 2000, 19:309-317.
137. Gersdorff N., Muller M., Otto S., Poschadel R., Hubner S., Miosge N. Basement membrane composition in the early mouse embryo day 7. Dev. Dyn. 2005, 233:1140-1148.
138. Henry M.D., Campbell K.P. Dystroglycan inside and out. Curr. Opin. Cell Biol. 1999, 11:602-607.
139. Williamson R.A., Henry M.D., Daniels K.J., Hrstka R.F., Lee J.C., Sunada Y., Ibraghimov-Beskrovnaya O., Campbell K.P. Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum. Mol. Genet. 1997, 6:831-841.
140. Henry M.D., Satz J.S., Brakebusch C., Costell M., Gustafsson E., Fassler R., Campbell K.P. Distinct roles for dystroglycan, beta1 integrin and perlecan in cell surface laminin organization. J. Cell Sci. 2001, 114:1137-1144.
141. Woodall B.P., Nystrom A., Iozzo R.A., Eble J.A., Niland S., Krieg T., Eckes B., Pozzi A., Iozzo R.V. Integrin alpha2beta1 is the required receptor for endorepellin angiostatic activity. J. Biol. Chem. 2008, 283:2335-2343.
142. Goyal A., Poluzzi C., Willis C.D., Smythies J., Shellard A., Neill T., Iozzo R.V. Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1alpha and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation. J Biol Chem 2012, 287:43543-43556.
143. Zoeller J.J., Whitelock J.M., Iozzo R.V. Perlecan regulates developmental angiogenesis by modulating the VEGF-VEGFR2 axis. Matrix Biol. 2009, 28:284-291.
144. Handler M., Yurchenco P.D., Iozzo R.V. Developmental expression of perlecan during murine embryogenesis. Dev. Dyn. 1997, 210:130-145.
145. Smith S.M., Shu C., Melrose J. Comparative immunolocalisation of perlecan with collagen II and aggrecan in human foetal, newborn and adult ovine joint tissues demonstrates perlecan as an early developmental chondrogenic marker. Histochem. Cell Biol. 2010, 134:251-263.
146. Arikawa-Hirasawa E., Le A.H., Nishino I., Nonaka I., Ho N.C., Francomano C.A., Govindraj P., Hassell J.R., Devaney J.M., Spranger J., Stevenson R.E., Iannaccone S., Dalakas M.C., Yamada Y. Structural and functional mutations of the perlecan gene cause Schwartz-Jampel syndrome, with myotonic myopathy and chondrodysplasia. Am. J. Hum. Genet. 2002, 70:1368-1375.
147. Bangratz M., Sarrazin N., Devaux J., Zambroni D., Echaniz-Laguna A., Rene F., Boerio D., Davoine C.S., Fontaine B., Feltri M.L., Benoit E., Nicole S. A mouse model of Schwartz-Jampel syndrome reveals myelinating Schwann cell dysfunction with persistent axonal depolarization in vitro and distal peripheral nerve hyperexcitability when perlecan is lacking. Am. J. Pathol. 2012, 180:2040-2055.
148. Ishijima M., Suzuki N., Hozumi K., Matsunobu T., Kosaki K., Kaneko H., Hassell J.R., Arikawa-Hirasawa E., Yamada Y. Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation. Matrix Biol. 2012, 31:234-245.
149. Fuki I.V., Iozzo R.V., Williams K.J. Perlecan heparan sulfate proteoglycan: a novel receptor that mediates a distinct pathway for ligand catabolism. J. Biol. Chem. 2000, 275:25742-25750.
150. Whitelock J.M., Graham L.D., Melrose J., Murdoch A.D., Iozzo R.V., Underwood P.A. Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells. Matrix Biol. 1999, 18:163-178.
151. Lord M.S., Chuang C.Y., Melrose J., Davies M.J., Iozzo R.V., Whitelock J.M. The role of vascular-derived perlecan in modulating cell adhesion, proliferation and growth factor signaling. Matrix Biol. 2014, 35:112-122.
152. Laplante P., Raymond M.A., Labelle A., Abe J., Iozzo R.V., Hebert M.J. Perlecan proteolysis induces an alpha2beta1 integrin- and Src family kinase-dependent anti-apoptotic pathway in fibroblasts in the absence of focal adhesion kinase activation. J. Biol. Chem. 2006, 281:30383-30392.
153. Kaneko H., Ishijima M., Futami I., Tomikawa-Ichikawa N., Kosaki K., Sadatsuki R., Yamada Y., Kurosawa H., Kaneko K., Arikawa-Hirasawa E. Synovial perlecan is required for osteophyte formation in knee osteoarthritis. Matrix Biol. 2013, 32:178-187.
154. Baker A.B., Ettenson D.S., Jonas M., Nugent M.A., Iozzo R.V., Edelman E.R. Endothelial cells provide feedback control for vascular remodeling through a mechanosensitive autocrine TGF-beta signaling pathway. Circ. Res. 2008, 103:289-297.
155. Wilusz R.E., Defrate L.E., Guilak F. A biomechanical role for perlecan in the pericellular matrix of articular cartilage. Matrix Biol. 2012, 31:320-327.
156. Wilusz R.E., Sanchez-Adams J., Guilak F. The structure and function of the pericellular matrix of articular cartilage. Matrix Biol. 2014, 39:25-32.
157. Park Y., Rangel C., Reynolds M.M., Caldwell M.C., Johns M., Nayak M., Welsh C.J., McDermott S., Datta S. Drosophila perlecan modulates FGF and hedgehog signals to activate neural stem cell division. Dev. Biol. 2003, 253:247-257.
158. Klein G., Conzelmann S., Beck S., Timpl R., Muller C.A. Perlecan in human bone marrow: a growth-factor-presenting, but anti-adhesive, extracellular matrix component for hematopoietic cells. Matrix Biol. 1995, 14:457-465.
159. Lord M.S., Jung M., Cheng B., Whitelock J.M. Transcriptional complexity of the HSPG2 gene in the human mast cell line, HMC-1. Matrix Biol. 2014, 35:123-131.
160. Jung M., Lord M.S., Cheng B., Lyons J.G., Alkhouri H., Hughes J.M., McCarthy S.J., Iozzo R.V., Whitelock J.M. Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: a role in angiogenesis and wound healing. J. Biol. Chem. 2013, 288:3289-3304.
161. Giros A., Morante J., Gil-Sanz C., Fairen A., Costell M. Perlecan controls neurogenesis in the developing telencephalon. BMC Dev. Biol. 2007, 7:29.
162. Xu Y.X., Ashline D., Liu L., Tassa C., Shaw S.Y., Ravid K., Layne M.D., Reinhold V., Robbins P.W. The glycosylation-dependent interaction of perlecan core protein with LDL: implications for atherosclerosis. J. Lipid Res. 2015, 56:266-276.
163. Arikawa-Hirasawa E., Watanabe H., Takami H., Hassell J.R., Yamada Y. Perlecan is essential for cartilage and cephalic development. Nat. Genet. 1999, 23:354-358.
164. Costell M., Gustafsson E., Aszodi A., Morgelin M., Bloch W., Hunziker E., Addicks K., Timpl R., Fassler R. Perlecan maintains the integrity of cartilage and some basement membranes. J. Cell Biol. 1999, 147:1109-1122.
165. Zoeller J.J., McQuillan A., Whitelock J., Ho S.Y., Iozzo R.V. A central function for perlecan in skeletal muscle and cardiovascular development. J. Cell Biol. 2008, 181:381-394.
166. Costell M., Carmona R., Gustafsson E., Gonzalez-Iriarte M., Fassler R., Munoz-Chapuli R. Hyperplastic conotruncal endocardial cushions and transposition of great arteries in perlecan-null mice. Circ. Res. 2002, 91:158-164.
167. Gonzalez-Iriarte M., Carmona R., Perez-Pomares J.M., Macias D., Costell M., Munoz-Chapuli R. Development of the coronary arteries in a murine model of transposition of great arteries. J. Mol. Cell. Cardiol. 2003, 35:795-802.
168. Rossi M., Morita H., Sormunen R., Airenne S., Kreivi M., Wang L., Fukai N., Olsen B.R., Tryggvason K., Soininen R. Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J. 2003, 22:236-245.
169. Lindner J.R., Hillman P.R., Barrett A.L., Jackson M.C., Perry T.L., Park Y., Datta S. The Drosophila perlecan gene trol regulates multiple signaling pathways in different developmental contexts. BMC Dev. Biol. 2007, 7:121.
170. Grigorian M., Liu T., Banerjee U., Hartenstein V. The proteoglycan Trol controls the architecture of the extracellular matrix and balances proliferation and differentiation of blood progenitors in the Drosophila lymph gland. Dev. Biol. 2013, 384:301-312.
171. Iozzo R.V., Murdoch A.D. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. FASEB J. 1996, 10:598-614.
172. Nugent M.A., Iozzo R.V. Fibroblast growth factor-2. Int. J. Biochem. Cell Biol. 2000, 32:115-120.
173. Muthusamy A., Cooper C.R., Gomes R.R. Soluble perlecan domain I enhances vascular endothelial growth factor-165 activity and receptor phosphorylation in human bone marrow endothelial cells. BMC Biochem. 2010, 11:43.
174. Nugent M.A., Nugent H.M., Iozzo R.V., Sanchack K., Edelman E.R. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6722-6727.
175. Whitelock J.M., Murdoch A.D., Iozzo R.V., Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 1996, 271:10079-10086.
176. d'Ortho M.P., Will H., Atkinson S., Butler G., Messent A., Gavrilovic J., Smith B., Timpl R., Zardi L., Murphy G. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur. J. Biochem. 1997, 250:751-757.
177. Deryugina E.I., Quigley J.P. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim. Biophys. Acta 2010, 1803:103-120.
178. Iozzo R.V., Cohen I.R., Grassel S., Murdoch A.D. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem. J. 1994, 302(Pt 3):625-639.
179. Iozzo R.V., Zoeller J.J., Nystrom A. Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol. Cells 2009, 27:503-513.
180. Iozzo R.V., Cohen I. Altered proteoglycan gene expression and the tumor stroma. Experientia 1993, 49:447-455.
181. Iozzo R.V. Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab. Investig. 1995, 73:157-160.
182. Murdoch A.D., Liu B., Schwarting R., Tuan R.S., Iozzo R.V. Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J. Histochem. Cytochem. 1994, 42:239-249.
183. Chang J.W., Kang U.B., Kim D.H., Yi J.K., Lee J.W., Noh D.Y., Lee C., Yu M.H. Identification of circulating endorepellin LG3 fragment: potential use as a serological biomarker for breast cancer. Proteomics Clin. Appl. 2008, 2:23-32.
184. Cohen I.R., Murdoch A.D., Naso M.F., Marchetti D., Berd D., Iozzo R.V. Abnormal expression of perlecan proteoglycan in metastatic melanomas. Cancer Res. 1994, 54:5771-5774.
185. Aviezer D., Iozzo R.V., Noonan D.M., Yayon A. Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol. Cell. Biol. 1997, 17:1938-1946.
186. Sharma B., Handler M., Eichstetter I., Whitelock J.M., Nugent M.A., Iozzo R.V. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J. Clin. Invest. 1998, 102:1599-1608.
187. Datta M.W., Hernandez A.M., Schlicht M.J., Kahler A.J., DeGueme A.M., Dhir R., Shah R.B., Farach-Carson C., Barrett A., Datta S. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway. Mol. Cancer 2006, 5:9.
188. Mathiak M., Yenisey C., Grant D.S., Sharma B., Iozzo R.V. A role for perlecan in the suppression of growth and invasion in fibrosarcoma cells. Cancer Res. 1997, 57:2130-2136.
189. Mongiat M., Sweeney S.M., San Antonio J.D., Fu J., Iozzo R.V. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 2003, 278:4238-4249.
190. Murdoch A.D., Dodge G.R., Cohen I., Tuan R.S., Iozzo R.V. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan), A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J. Biol. Chem. 1992, 267:8544-8557.
191. Bix G., Fu J., Gonzalez E.M., Macro L., Barker A., Campbell S., Zutter M.M., Santoro S.A., Kim J.K., Hook M., Reed C.C., Iozzo R.V. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J. Cell Biol. 2004, 166:97-109.
192. Goyal A., Pal N., Concannon M., Paul M., Doran M., Poluzzi C., Sekiguchi K., Whitelock J.M., Neill T., Iozzo R.V. Endorepellin, the angiostatic module of perlecan, interacts with both the alpha2beta1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism. J. Biol. Chem. 2011, 286:25947-25962.
193. Gonzalez E.M., Reed C.C., Bix G., Fu J., Zhang Y., Gopalakrishnan B., Greenspan D.S., Iozzo R.V. BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J. Biol. Chem. 2005, 280:7080-7087.
194. Cailhier J.F., Sirois I., Laplante P., Lepage S., Raymond M.A., Brassard N., Prat A., Iozzo R.V., Pshezhetsky A.V., Hebert M.J. Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. J. Biol. Chem. 2008, 283:27220-27229.
195. Adkins J.N., Varnum S.M., Auberry K.J., Moore R.J., Angell N.H., Smith R.D., Springer D.L., Pounds J.G. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol. Cell. Proteomics 2002, 1:947-955.
196. West L., Govindraj P., Koob T.J., Hassell J.R. Changes in perlecan during chondrocyte differentiation in the fetal bovine rib growth plate. J. Orthop. Res. 2006, 24:1317-1326.
197. O'Riordan E., Orlova T.N., Mendelev N., Patschan D., Kemp R., Chander P.N., Hu R., Hao G., Gross S.S., Iozzo R.V., Delaney V., Goligorsky M.S. Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin. Appl. 2008, 2:1025-1035.
198. Cao Z., Maupin K., Curnutte B., Fallon B., Feasley C.L., Brouhard E., Kwon R., West C.M., Cunningham J., Brand R., Castelli P., Crippa S., Feng Z., Allen P., Simeone D.M., Haab B.B. Specific glycoforms of MUC5AC and endorepellin accurately distinguish mucinous from nonmucinous pancreatic cysts. Mol. Cell. Proteomics 2013, 12:2724-2734.
199. Gonzalez E.M., Mongiat M., Slater S.J., Baffa R., Iozzo R.V. A novel interaction between perlecan protein core and progranulin: potential effects on tumor growth. J. Biol. Chem. 2003, 278:38113-38116.
200. Mongiat M., Fu J., Oldershaw R., Greenhalgh R., Gown A.M., Iozzo R.V. Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J. Biol. Chem. 2003, 278:17491-17499.
201. Saarela J., Rehn M., Oikarinen A., Autio-Harmainen H., Pihlajaniemi T. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am. J. Pathol. 1998, 153:611-626.
202. Nystrom A., Shaik Z.P., Gullberg D., Krieg T., Eckes B., Zent R., Pozzi A., Iozzo R.V. Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity. Blood 2009, 114:4897-4906.
203. Bix G., Castello R., Burrows M., Zoeller J.J., Weech M., Iozzo R.A., Cardi C., Thakur M.L., Barker C.A., Camphausen K., Iozzo R.V. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J. Natl. Cancer Inst. 2006, 98:1634-1646.
204. San Antonio J.D., Zoeller J.J., Habursky K., Turner K., Pimtong W., Burrows M., Choi S., Basra S., Bennett J.S., DeGrado W.F., Iozzo R.V. A key role for the integrin alpha2beta1 in experimental and developmental angiogenesis. Am. J. Pathol. 2009, 175:1338-1347.
205. Willis C.D., Poluzzi C., Mongiat M., Iozzo R.V. Endorepellin laminin-like globular 1/2 domains bind Ig3-5 of vascular endothelial growth factor (VEGF) receptor 2 and block pro-angiogenic signaling by VEGFA in endothelial cells. FEBS J 2013, 280:2271-2284.
206. Koch S., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb. Perspect. Med. 2012, 2:a006502.
207. Le B.V., Kim H., Choi J., Kim J.H., Hahn M.J., Lee C., Kim K.K., Hwang H.Y. Crystal structure of the LG3 domain of endorepellin, an angiogenesis inhibitor. J. Mol. Biol. 2011, 414:231-242.
208. Buraschi S., Neill T., Goyal A., Poluzzi C., Smythies J., Owens R.T., Schaefer L., Torres A., Iozzo R.V. Decorin causes autophagy in endothelial cells via Peg3. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E2582-E2591.
209. Douglass S., Goyal A., Iozzo R.V. The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy. Connect. Tissue Res. 2015, 56:1-11.
210. Tan H., Yang S., Feng Y., Liu C., Cao J., Mu G., Wang F. Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin. J. Biochem. 2008, 144:207-213.
211. Bai Y., Zhao M., Zhang C., Li S., Qi Y., Wang B., Huang L., Li X. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization. PLoS One 2014, 9:e112448.
212. Ling Y., Yang Y., Lu N., You Q.D., Wang S., Gao Y., Chen Y., Guo Q.L. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem. Biophys. Res. Commun. 2007, 361:79-84.
213. Calvo A., Yokoyama Y., Smith L.E., Ali I., Shih S.C., Feldman A.L., Libutti S.K., Sundaram R., Green J.E. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int. J. Cancer 2002, 101:224-234.
214. Yokoyama Y., Ramakrishnan S. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth. Cancer 2005, 104:321-331.
215. Meyer A., Auernheimer J., Modlinger A., Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des. 2006, 12:2723-2747.
216. Yokoyama Y., Ramakrishnan S. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int. J. Cancer 2004, 111:839-848.
217. Fu Y., Tang H., Huang Y., Song N., Luo Y. Unraveling the mysteries of endostatin. IUBMB Life 2009, 61:613-626.
218. Kisker O., Becker C.M., Prox D., Fannon M., D'Amato R., Flynn E., Fogler W.E., Sim B.K., Allred E.N., Pirie-Shepherd S.R., Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001, 61:7669-7674.
219. Xia H., Luo L.M., Fan Y.F., Tong W.C., Wen J.X. Inhibitory effect of recombinant human endostatin on angiogenesis and lung metastasis of mouse lung adenocarcinoma LA795. Di Yi Jun Yi Da Xue Xue Bao 2003, 23:30-33.
220. Feldman A.L., Alexander H.R., Hewitt S.M., Lorang D., Thiruvathukal C.E., Turner E.M., Libutti S.K. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J. Natl. Cancer Inst. 2001, 93:1014-1020.
221. Sauter B.V., Martinet O., Zhang W.J., Mandeli J., Woo S.L. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4802-4807.
222. Nguyen J.T., Wu P., Clouse M.E., Hlatky L., Terwilliger E.F. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res. 1998, 58:5673-5677.
223. Blezinger P., Wang J., Gondo M., Quezada A., Mehrens D., French M., Singhal A., Sullivan S., Rolland A., Ralston R., Min W. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol. 1999, 17:343-348.
224. Chen Q.R., Kumar D., Stass S.A., Mixson A.J. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res. 1999, 59:3308-3312.
225. Sacco M.G., Cato E.M., Ceruti R., Soldati S., Indraccolo S., Caniatti M., Scanziani E., Vezzoni P. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. Gene Ther. 2001, 8:67-70.
226. Ding I., Sun J.Z., Fenton B., Liu W.M., Kimsely P., Okunieff P., Min W. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res. 2001, 61:526-531.
227. Read T.A., Farhadi M., Bjerkvig R., Olsen B.R., Rokstad A.M., Huszthy P.C., Vajkoczy P. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res. 2001, 61:6830-6837.
228. Read T.A., Sorensen D.R., Mahesparan R., Enger P.O., Timpl R., Olsen B.R., Hjelstuen M.H., Haraldseth O., Bjerkvig R. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat. Biotechnol. 2001, 19:29-34.
229. Joki T., Machluf M., Atala A., Zhu J., Seyfried N.T., Dunn I.F., Abe T., Carroll R.S., Black P.M. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat. Biotechnol. 2001, 19:35-39.
230. Schuch G., Oliveira-Ferrer L., Loges S., Laack E., Bokemeyer C., Hossfeld D.K., Fiedler W., Ergun S. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia 2005, 19:1312-1317.
231. Schmidt N.O., Ziu M., Carrabba G., Giussani C., Bello L., Sun Y., Schmidt K., Albert M., Black P.M., Carroll R.S. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clin. Cancer Res. 2004, 10:1255-1262.
232. te Velde E.A., Reijerkerk A., Brandsma D., Vogten J.M., Wu Y., Kranenburg O., Voest E.E., Gebbink M., Borel Rinkes I.H. Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Br. J. Cancer 2005, 92:729-735.
233. Beck M.T., Chen N.Y., Franek K.J., Chen W.Y. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res. 2003, 63:3598-3604.
234. Cho H., Kim W.J., Lee Y.M., Kim Y.M., Kwon Y.G., Park Y.S., Choi E.Y., Kim K.W. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent. Oncol. Rep. 2004, 11:191-195.
235. Prox D., Becker C., Pirie-Shepherd S.R., Celik I., Folkman J., Kisker O. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J. Surg. 2003, 27:405-411.
236. Barnett F.H., Scharer-Schuksz M., Wood M., Yu X., Wagner T.E., Friedlander M. Intra-arterial delivery of endostatin gene to brain tumors prolongs survival and alters tumor vessel ultrastructure. Gene Ther. 2004, 11:1283-1289.
237. Dkhissi F., Lu H., Soria C., Opolon P., Griscelli F., Liu H., Khattar P., Mishal Z., Perricaudet M., Li H. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum. Gene Ther. 2003, 14:997-1008.
238. Shi W., Teschendorf C., Muzyczka N., Siemann D.W. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother. Oncol. 2003, 66:1-9.
239. Abraham D., Abri S., Hofmann M., Holtl W., Aharinejad S. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. J. Urol. 2003, 170:1388-1393.
240. Luo X., Slater J.M., Gridley D.S. Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63:553-564.
241. Wu Y., Yang L., Hu B., Liu J.Y., Su J.M., Luo Y., Ding Z.Y., Niu T., Li Q., Xie X.J., Wen Y.J., Tian L., Kan B., Mao Y.Q., Wei Y.Q. Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine. Anti-Cancer Drugs 2005, 16:551-557.
242. Kuo C.J., Farnebo F., Yu E.Y., Christofferson R., Swearingen R.A., Carter R., von Recum H.A., Yuan J., Kamihara J., Flynn E., D'Amato R., Folkman J., Mulligan R.C. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4605-4610.
243. Pawliuk R., Bachelot T., Zurkiya O., Eriksson A., Cao Y., Leboulch P. Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. Mol. Ther. 2002, 5:345-351.
244. Cui R., Takahashi K., Takahashi F., Tanabe K.K., Fukuchi Y. Endostatin gene transfer in murine lung carcinoma cells induces vascular endothelial growth factor secretion resulting in up-regulation of in vivo tumorigenecity. Cancer Lett. 2006, 232:262-271.
245. Eisterer W., Jiang X., Bachelot T., Pawliuk R., Abramovich C., Leboulch P., Hogge D., Eaves C. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol. Ther. 2002, 5:352-359.
246. Jouanneau E., Alberti L., Nejjari M., Treilleux I., Vilgrain I., Duc A., Combaret V., Favrot M., Leboulch P., Bachelot T. Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J. Neurooncol. 2001, 51:11-18.
247. Jin X., Bookstein R., Wills K., Avanzini J., Tsai V., LaFace D., Terracina G., Shi B., Nielsen L.L. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther. 2001, 8:982-989.
248. Celik I., Surucu O., Dietz C., Heymach J.V., Force J., Hoschele I., Becker C.M., Folkman J., Kisker O. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res. 2005, 65:11044-11050.
249. Reynolds A.R. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose-Response 2009, 8:253-284.
250. Hefler L., Tempfer C., Obermair A., Frischmuth K., Sliutz G., Reinthaller A., Leodolter S., Kainz C. Serum concentrations of vascular endothelial growth factor in vulvar cancer. Clin. Cancer Res. 1999, 5:2806-2809.
251. Zorick T.S., Mustacchi Z., Bando S.Y., Zatz M., Moreira-Filho C.A., Olsen B., Passos-Bueno M.R. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur. J. Hum. Genet. 2001, 9:811-814.
252. Homer J.J., Greenman J., Stafford N.D. Angiogenic cytokines in serum and plasma of patients with head and neck squamous cell carcinoma. Clin. Otolaryngol. Allied Sci. 2000, 25:570-576.
253. Musso O., Rehn M., Theret N., Turlin B., Bioulac-Sage P., Lotrian D., Campion J.P., Pihlajaniemi T., Clement B. Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res. 2001, 61:45-49.
254. Yamagata M., Shiratori Y., Dan Y., Shiina S., Takayama T., Makuuchi M., Omata M. Serum endostatin levels in patients with hepatocellular carcinoma. Ann. Oncol. 2000, 11:761-762.
255. Hefler L., Tempfer C., Kainz C., Obermair A. Serum concentrations of endostatin in patients with vulvar cancer. Gynecol. Oncol. 1999, 74:151-152.
256. Feldman A.L., Pak H., Yang J.C., Alexander H.R., Libutti S.K. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 2001, 91:1525-1529.
257. Feldman A.L., Tamarkin L., Paciotti G.F., Simpson B.W., Linehan W.M., Yang J.C., Fogler W.E., Turner E.M., Alexander H.R., Libutti S.K. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin. Cancer Res. 2000, 6:4628-4634.
258. Kuroi K., Tanaka C., Toi M. Circulating levels of endostatin in cancer patients. Oncol. Rep. 2001, 8:405-409.
259. Kim H.S., Lim S.J., Park Y.K. Anti-angiogenic factor endostatin in osteosarcoma. APMIS 2009, 117:716-723.
260. Hata K., Dhar D.K., Kanasaki H., Nakayama K., Fujiwaki R., Katabuchi H., Okamura H., Nagasue N., Miyazaki K. Serum endostatin levels in patients with epithelial ovarian cancer. Anticancer Res. 2003, 23:1907-1912.
261. Wrobel T., Mazur G., Kapelko K., Kuliczkowski K. Endostatin serum level in acute myeloid leukemia. Neoplasma 2005, 52:182-184.
262. Guan K.P., Ye H.Y., Yan Z., Wang Y., Hou S.K. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003, 61:719-723.
263. Feldman A.L., Alexander H.R., Bartlett D.L., Kranda K.C., Miller M.S., Costouros N.G., Choyke P.L., Libutti S.K. A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann. Surg. Oncol. 2001, 8:741-745.
264. Ratel D., Nasser V., Dupre I., Benabid A.L., Berger F. Antibodies to endostatin in a multifocal glioblastoma patient. Lancet 2000, 356:1656-1657.
265. Hebbar M., Peyrat J.P., Hornez L., Hatron P.Y., Hachulla E., Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum. 2000, 43:889-893.
266. Funatsu H., Yamashita H., Noma H., Shimizu E., Yamashita T., Hori S. Stimulation and inhibition of angiogenesis in diabetic retinopathy. Jpn. J. Ophthalmol. 2001, 45:577-584.
267. Sund M., Hamano Y., Sugimoto H., Sudhakar A., Soubasakos M., Yerramalla U., Benjamin L.E., Lawler J., Kieran M., Shah A., Kalluri R. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2934-2939.
268. Ma L., del Soldato P., Wallace J.L. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13243-13247.
269. Eder J.P., Supko J.G., Clark J.W., Puchalski T.A., Garcia-Carbonero R., Ryan D.P., Shulman L.N., Proper J., Kirvan M., Rattner B., Connors S., Keogan M.T., Janicek M.J., Fogler W.E., Schnipper L., Kinchla N., Sidor C., Phillips E., Folkman J., Kufe D.W. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol. 2002, 20:3772-3784.
270. Herbst R.S., Hess K.R., Tran H.T., Tseng J.E., Mullani N.A., Charnsangavej C., Madden T., Davis D.W., McConkey D.J., O'Reilly M.S., Ellis L.M., Pluda J., Hong W.K., Abbruzzese J.L. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 2002, 20:3792-3803.
271. Herbst R.S., Mullani N.A., Davis D.W., Hess K.R., McConkey D.J., Charnsangavej C., O'Reilly M.S., Kim H.W., Baker C., Roach J., Ellis L.M., Rashid A., Pluda J., Bucana C., Madden T.L., Tran H.T., Abbruzzese J.L. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J. Clin. Oncol. 2002, 20:3804-3814.
272. Thomas J.P., Arzoomanian R.Z., Alberti D., Marnocha R., Lee F., Friedl A., Tutsch K., Dresen A., Geiger P., Pluda J., Fogler W., Schiller J.H., Wilding G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 2003, 21:223-231.
273. Hansma A.H., Broxterman H.J., van der Horst I., Yuana Y., Boven E., Giaccone G., Pinedo H.M., Hoekman K. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. Ann. Oncol. 2005, 16:1695-1701.
274. Kulke M.H., Bergsland E.K., Ryan D.P., Enzinger P.C., Lynch T.J., Zhu A.X., Meyerhardt J.A., Heymach J.V., Fogler W.E., Sidor C., Michelini A., Kinsella K., Venook A.P., Fuchs C.S. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2006, 24:3555-3561.
275. Wang J., Sun Y., Liu Y., Yu Q., Zhang Y., Li K., Zhu Y., Zhou Q., Hou M., Guan Z., Li W., Zhuang W., Wang D., Liang H., Qin F., Lu H., Liu X., Sun H., Luo S., Yang R., Tu Y., Wang X., Song S., Zhou J., You L., Yao C. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 2005, 8:283-290.
276. Rong B., Yang S., Li W., Zhang W., Ming Z. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J. Surg. Oncol. 2012, 10:170.
277. Thadikkaran L., Crettaz D., Siegenthaler M.A., Gallot D., Sapin V., Iozzo R.V., Queloz P.A., Schneider P., Tissot J.D. The role of proteomics in the assessment of premature rupture of fetal membranes. Clin. Chim. Acta 2005, 360:27-36.
278. Vuadens F., Benay C., Crettaz D., Gallot D., Sapin V., Schneider P., Bienvenut W.V., Lemery D., Quadroni M., Dastugue B., Tissot J.D. Identification of biologic markers of the premature rupture of fetal membranes: proteomic approach. Proteomics 2003, 3:1521-1525.
279. Tsangaris G.T., Karamessinis P., Kolialexi A., Garbis S.D., Antsaklis A., Mavrou A., Fountoulakis M. Proteomic analysis of amniotic fluid in pregnancies with Down syndrome. Proteomics 2006, 6:4410-4419.
280. Krishna J., Shah Z.A., Merchant M., Klein J.B., Gozal D. Urinary protein expression patterns in children with sleep-disordered breathing: preliminary findings. Sleep Med. 2006, 7:221-227.
281. Saini M.G., Bix G.J. Oxygen-glucose deprivation (OGD) and interleukin-1 (IL-1) differentially modulate cathepsin B/L mediated generation of neuroprotective perlecan LG3 by neurons. Brain Res. 2012, 1438:65-74.
282. Saini M.G., Pinteaux E., Lee B., Bix G.J. Oxygen-glucose deprivation and interleukin-1alpha trigger the release of perlecan LG3 by cells of neurovascular unit. J. Neurochem. 2011, 119:760-771.
283. Laplante P., Raymond M.A., Gagnon G., Vigneault N., Sasseville A.M., Langelier Y., Bernard M., Raymond Y., Hebert M.J. Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J. Immunol. 2005, 174:5740-5749.
284. Oda O., Shinzato T., Ohbayashi K., Takai I., Kunimatsu M., Maeda K., Yamanaka N. Purification and characterization of perlecan fragment in urine of end-stage renal failure patients. Clin. Chim. Acta 1996, 255:119-132.
285. Wang H., Listrat A., Meunier B., Gueugneau M., Coudy-Gandilhon C., Combaret L., Taillandier D., Polge C., Attaix D., Lethias C., Lee K., Goh K.L., Bechet D. Apoptosis in capillary endothelial cells in ageing skeletal muscle. Aging Cell 2014, 13:254-262.
286. Majek P., Reicheltova Z., Suttnar J., Cermak J., Dyr J.E. Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. Proteome Sci. 2011, 9:64.
287. Gronborg M., Kristiansen T.Z., Iwahori A., Chang R., Reddy R., Sato N., Molina H., Jensen O.N., Hruban R.H., Goggins M.G., Maitra A., Pandey A. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5:157-171.
288. Neill T., Schaefer L., Iozzo R.V. Instructive roles of extracellular matrix on autophagy. Am. J. Pathol. 2014, 184:2146-2153.
289. Ramchandran R., Dhanabal M., Volk R., Waterman M.J., Segal M., Lu H., Knebelmann B., Sukhatme V.P. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem. Biophys. Res. Commun. 1999, 255:735-739.
290. Folkman J. Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin. Sci. STKE 2006, 2006:e35.
291. Li M., Huang X., Zhu Z., Wong M., Watkins S., Zhao Q., Herberman R., Gorelik E. Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin. J. Immunother. 2001, 24:472-481.
292. Yamanaka R., Zullo S.A., Ramsey J., Onodera M., Tanaka R., Blaese M., Xanthopoulos K.G. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther. 2001, 8:796-802.
293. Szary J., Szala S. Intra-tumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal carcinoma growth. Int. J. Cancer 2001, 91:835-839.
294. Li G.C., Nie M.M., Yang J.M., Su C.Q., Sun L.C., Qian Y.Z., Sham J., Fang G.E., Wu M.C., Qian Q.J. Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin. Zhonghua Yi Xue Za Zhi 2004, 84:943-948.
295. Fu G.F., Li X., Hou Y.Y., Fan Y.R., Liu W.H., Xu G.X. Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther. 2005, 12:133-140.
296. Li L., Huang J.L., Liu Q.C., Wu P.H., Liu R.Y., Zeng Y.X., Huang W.L. Endostatin gene therapy for liver cancer by a recombinant adenovirus delivery. World J. Gastroenterol. 2004, 10:1867-1871.
297. Kikuchi E., Menendez S., Ohori M., Cordon-Cardo C., Kasahara N., Bochner B.H. Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin. Clin. Cancer Res. 2004, 10:1835-1842.
298. Kurdow R., Boehle A.S., Ruhnke M., Mendoza R., Boenicke L., Sipos B., Schniewind B., Dohrmann P., Kalthoff H. Retroviral endostatin gene transfer inhibits growth of human lung cancer in a murine orthotopic xenotransplant model. Langenbeck's Arch. Surg. 2003, 388:401-405.
299. Raymond M.A., Desormeaux A., Laplante P., Vigneault N., Filep J.G., Landry K., Pshezhetsky A.V., Hebert M.J. Apoptosis of endothelial cells triggers a caspase-dependent anti-apoptotic paracrine loop active on VSMC. FASEB J. 2004, 18:705-707.